Systemic therapy Common adverse drug reactions (≥1% of patients) associated with systemic<unk>  therapy (oral or IV) include nausea, vomiting, diarrhea, encephalopathy (with IV use only), injection site reactions (with IV use only) and headache. In high doses, hallucinations have been reported. Infrequent adverse effects (0.1–1% of patients) include agitation, vertigo, confusion, dizziness, oedema, arthralgia, sore throat, constipation, abdominal pain, hair loss, rash and weakness. Rare adverse effects (<0.1% of patients) include coma, seizures, neutropenia, leukopenia, crystalluria, anorexia, fatigue, hepatitis, Stevens–Johnson syndrome, toxic epidermal necrolysis, thrombotic thrombocytopenic purpura and anaphylaxis. Intravenous<unk>  may cause reversible nephrotoxicity in up to 5% to 10% of patients because of precipitation of<unk>  crystals in the kidney.<unk>  crystalline nephropathy is more common when<unk>  is given as a rapid infusion and in patients with dehydration and preexisting renal impairment. Adequate hydration, a slower rate of infusion, and dosing based on renal function may reduce this risk. The<unk>  metabolite 9-carboxymethoxymethylguanine (9-CMMG) has been shown to play a role in neurological adverse events, particularly in older people and those with reduced renal function. Topical therapy<unk>  topical cream is commonly associated (≥1% of patients) with: dry or flaking skin or transient stinging/burning sensations. Infrequent adverse effects include erythema or itch. When applied to the eye,<unk>  is commonly associated (≥1% of patients) with transient mild stinging. Infrequently (0.1–1% of patients), ophthalmic<unk>  is associated with superficial punctate keratitis or allergic reactions.
Aciclovir
Penciclovir
Valganciclovir
Famciclovir
Ganciclovir
Alcaftadine
Benzylpenicillin
Amantadine